Login to Your Account



OSI, Genentech Receive FDA Approval Of Tarceva For NSCLC

By Aaron Lorenzo


Monday, November 22, 2004
The FDA approved a new lung cancer drug, Tarceva (erlotinib), but a surprise in the agency's authorization might have driven down share values in the companies that developed it - OSI Pharmaceuticals Inc. and Genentech Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription